Annual SGA
$264.12 M
-$1.42 M-0.54%
December 31, 2024
Summary
- As of February 26, 2025, TVTX annual SGA is $264.12 million, with the most recent change of -$1.42 million (-0.54%) on December 31, 2024.
- During the last 3 years, TVTX annual SGA has risen by +$137.84 million (+109.15%).
- TVTX annual SGA is now -0.54% below its all-time high of $265.54 million, reached on December 31, 2023.
Performance
TVTX SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$69.50 M
+$3.88 M+5.92%
December 1, 2024
Summary
- As of February 26, 2025, TVTX quarterly SGA is $69.50 million, with the most recent change of +$3.88 million (+5.92%) on December 1, 2024.
- Over the past year, TVTX quarterly SGA has increased by +$5.91 million (+9.30%).
- TVTX quarterly SGA is now at all-time high.
Performance
TVTX Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$5.43 B
-$321.55 M-6.30%
December 1, 2024
Summary
- As of February 26, 2025, TVTX TTM SGA is -$5.43 billion, with the most recent change of -$321.55 million (-6.30%) on December 1, 2024.
- Over the past year, TVTX TTM SGA has dropped by -$5.69 billion (-2144.06%).
- TVTX TTM SGA is now -4474627.95% below its all-time high of -$121.30 thousand.
Performance
TVTX TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
TVTX Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -0.5% | +9.3% | -2144.1% |
| 3 y3 years | +109.2% | +9.3% | -2144.1% |
| 5 y5 years | +104.8% | +9.3% | -2144.1% |
TVTX Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -0.5% | +109.2% | at high | +276.2% | -93.9% | at low |
| 5 y | 5-year | -0.5% | +109.2% | at high | +276.2% | -270.9% | at low |
| alltime | all time | -0.5% | >+9999.0% | at high | >+9999.0% | <-9999.0% | at low |
Travere Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $264.12 M(-0.5%) | - | - |
| Dec 2024 | - | $69.50 M(+5.9%) | $264.12 M(+2.3%) |
| Sep 2024 | - | $65.62 M(+1.3%) | $258.21 M(-0.8%) |
| Jun 2024 | - | $64.78 M(+0.9%) | $260.39 M(-1.3%) |
| Mar 2024 | - | $64.22 M(+1.0%) | $263.81 M(-0.7%) |
| Dec 2023 | $265.54 M(+34.4%) | $63.59 M(-6.2%) | $265.54 M(+2.5%) |
| Sep 2023 | - | $67.80 M(-0.6%) | $259.04 M(+6.3%) |
| Jun 2023 | - | $68.20 M(+3.4%) | $243.66 M(+6.7%) |
| Mar 2023 | - | $65.95 M(+15.5%) | $228.44 M(+9.2%) |
| Dec 2022 | $197.52 M(+56.4%) | $57.09 M(+8.9%) | $209.27 M(+22.6%) |
| Sep 2022 | - | $52.42 M(-1.1%) | $170.66 M(+10.6%) |
| Jun 2022 | - | $52.98 M(+13.2%) | $154.31 M(+13.2%) |
| Mar 2022 | - | $46.79 M(+153.2%) | $136.29 M(+7.9%) |
| Dec 2021 | $126.28 M(-7.0%) | $18.48 M(-48.8%) | $126.28 M(-12.0%) |
| Sep 2021 | - | $36.06 M(+3.1%) | $143.55 M(+3.0%) |
| Jun 2021 | - | $34.97 M(-4.9%) | $139.43 M(-0.0%) |
| Mar 2021 | - | $36.78 M(+2.9%) | $139.44 M(+2.7%) |
| Dec 2020 | $135.80 M(+5.3%) | $35.74 M(+11.9%) | $135.80 M(+6.4%) |
| Sep 2020 | - | $31.95 M(-8.6%) | $127.59 M(+1.7%) |
| Jun 2020 | - | $34.97 M(+5.5%) | $125.42 M(-3.1%) |
| Mar 2020 | - | $33.14 M(+20.4%) | $129.42 M(+0.4%) |
| Dec 2019 | $128.95 M(+24.4%) | $27.53 M(-7.5%) | $128.95 M(+1.2%) |
| Sep 2019 | - | $29.78 M(-23.6%) | $127.40 M(+3.0%) |
| Jun 2019 | - | $38.97 M(+19.3%) | $123.72 M(+12.6%) |
| Mar 2019 | - | $32.67 M(+25.8%) | $109.86 M(+6.0%) |
| Dec 2018 | $103.65 M(-0.3%) | $25.98 M(-0.5%) | $103.65 M(-1.2%) |
| Sep 2018 | - | $26.11 M(+4.0%) | $104.95 M(+1.2%) |
| Jun 2018 | - | $25.10 M(-5.2%) | $103.69 M(-3.5%) |
| Mar 2018 | - | $26.47 M(-3.0%) | $107.43 M(+3.2%) |
| Dec 2017 | $103.96 M | $27.27 M(+9.7%) | $104.08 M(+1.0%) |
| Sep 2017 | - | $24.85 M(-13.8%) | $103.03 M(-3.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | $28.84 M(+24.7%) | $106.86 M(+5.6%) |
| Mar 2017 | - | $23.11 M(-11.9%) | $101.22 M(+4.1%) |
| Dec 2016 | $97.15 M(+22.1%) | $26.23 M(-8.5%) | $97.23 M(+3.8%) |
| Sep 2016 | - | $28.68 M(+23.6%) | $93.69 M(+7.3%) |
| Jun 2016 | - | $23.20 M(+21.3%) | $87.32 M(+4.2%) |
| Mar 2016 | - | $19.13 M(-15.7%) | $83.81 M(+5.4%) |
| Dec 2015 | $79.54 M(+33.4%) | $22.68 M(+1.7%) | $79.54 M(+6.9%) |
| Sep 2015 | - | $22.31 M(+13.3%) | $74.40 M(+7.1%) |
| Jun 2015 | - | $19.69 M(+32.6%) | $69.47 M(+17.0%) |
| Mar 2015 | - | $14.86 M(-15.3%) | $59.35 M(-0.5%) |
| Dec 2014 | $59.65 M(+237.2%) | $17.55 M(+1.0%) | $59.65 M(+20.8%) |
| Sep 2014 | - | $17.37 M(+81.4%) | $49.40 M(+38.1%) |
| Jun 2014 | - | $9.58 M(-36.8%) | $35.78 M(+16.8%) |
| Mar 2014 | - | $15.15 M(+107.5%) | $30.64 M(+77.9%) |
| Dec 2013 | $17.69 M(-40.2%) | $7.30 M(+94.4%) | $17.22 M(+73.5%) |
| Sep 2013 | - | $3.75 M(-15.5%) | $9.93 M(+60.8%) |
| Jun 2013 | - | $4.44 M(+157.2%) | $6.17 M(+255.7%) |
| Mar 2013 | - | $1.73 M(>+9900.0%) | $1.74 M(>+9900.0%) |
| Dec 2012 | $29.59 M(>+9900.0%) | - | - |
| Nov 2012 | - | $3200.00(+6.7%) | $13.00 K(+1.6%) |
| Aug 2012 | - | $3000.00(0.0%) | $12.80 K(0.0%) |
| May 2012 | - | $3000.00(-21.1%) | $12.80 K(0.0%) |
| Feb 2012 | - | $3800.00(+26.7%) | $12.80 K(+1.6%) |
| Feb 2012 | $12.80 K(+0.8%) | - | - |
| Nov 2011 | - | $3000.00(0.0%) | $12.60 K(-0.8%) |
| Aug 2011 | - | $3000.00(0.0%) | $12.70 K(0.0%) |
| May 2011 | - | $3000.00(-16.7%) | $12.70 K(0.0%) |
| Feb 2011 | $12.70 K | $3600.00(+16.1%) | $12.70 K(+39.6%) |
| Nov 2010 | - | $3100.00(+3.3%) | $9100.00(+51.7%) |
| Aug 2010 | - | $3000.00(0.0%) | $6000.00(+100.0%) |
| May 2010 | - | $3000.00 | $3000.00 |
FAQ
- What is Travere Therapeutics annual SGA?
- What is the all time high annual SGA for Travere Therapeutics?
- What is Travere Therapeutics annual SGA year-on-year change?
- What is Travere Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Travere Therapeutics?
- What is Travere Therapeutics quarterly SGA year-on-year change?
- What is Travere Therapeutics TTM SGA?
- What is the all time high TTM SGA for Travere Therapeutics?
- What is Travere Therapeutics TTM SGA year-on-year change?
What is Travere Therapeutics annual SGA?
The current annual SGA of TVTX is $264.12 M
What is the all time high annual SGA for Travere Therapeutics?
Travere Therapeutics all-time high annual SGA is $265.54 M
What is Travere Therapeutics annual SGA year-on-year change?
Over the past year, TVTX annual SGA has changed by -$1.42 M (-0.54%)
What is Travere Therapeutics quarterly SGA?
The current quarterly SGA of TVTX is $69.50 M
What is the all time high quarterly SGA for Travere Therapeutics?
Travere Therapeutics all-time high quarterly SGA is $69.50 M
What is Travere Therapeutics quarterly SGA year-on-year change?
Over the past year, TVTX quarterly SGA has changed by +$5.91 M (+9.30%)
What is Travere Therapeutics TTM SGA?
The current TTM SGA of TVTX is -$5.43 B
What is the all time high TTM SGA for Travere Therapeutics?
Travere Therapeutics all-time high TTM SGA is -$121.30 K
What is Travere Therapeutics TTM SGA year-on-year change?
Over the past year, TVTX TTM SGA has changed by -$5.69 B (-2144.06%)